Pharma BD Deal Intelligence

Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business)

2021 · Acquisition/Merger · $875M · Complete

Thermo Fisher Scientific agreed to acquire Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for approximately EUR 725M (~$875M) cash. The acquisition expanded Thermo Fisher's gene therapy CDMO capabilities.

Key facts

• Announced Apr 15, 2021
• Deal value $875M
• Deal type Acquisition/Merger
• Therapeutic area Cell and gene therapy CDMO
• Indications Cell and gene therapy CDMO
• Key assets Viral vector manufacturing capabilities (Belgium)
• Mechanism Viral vector contract manufacturing for gene therapies

← Browse all deals  ·  How we score deals